Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer

Kotaro Shibahara, Manabu Yamamoto, Yoshihiro Kakeji, Hisanobu Sakata, Yoshihiko Maehara

Research output: Contribution to journalArticle

Abstract

The aim of this study was to compare the efficacy and toxicity of S-l to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients. Patients and Methods: Fifty-two patients were treated with either S-l (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively. Results: There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-l group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-l and 12 months with UFT/LV. Conclusion: The oral S-l provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.

Original languageEnglish
Pages (from-to)1779-1784
Number of pages6
JournalAnticancer research
Volume28
Issue number3 B
Publication statusPublished - May 2008

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Shibahara, K., Yamamoto, M., Kakeji, Y., Sakata, H., & Maehara, Y. (2008). Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer. Anticancer research, 28(3 B), 1779-1784.